AIC
NBIX icon

Ameritas Investment Company’s Neurocrine Biosciences NBIX Stock Holding History

Ameritas Investment Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5
Closed -$486 – 1576
2021
Q1 		$486 Buy
+5
New +$524 ﹤0.01% 2180
2019
Q1 		– Sell
-12
Closed -$1K – 1493
2018
Q4 		$1K Buy
+12
New +$1.15K ﹤0.01% 1441

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return

Ameritas Investment Company's NBIX Position: Q2 2021 in Review

Ameritas Investment Company sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 5 shares — an estimated $486 sold.

Ameritas Investment Company first reported a position in NBIX in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q4 2018. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Ameritas Investment Company reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 5 Neurocrine Biosciences shares in Q2 2021, an estimated $486.
  • Ameritas Investment Company first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 2 quarters.
  • Ameritas Investment Company's Neurocrine Biosciences position peaked at $1K in Q4 2018.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.